Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
California State Teachers Retirement System boosted its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 2,222.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 80,845 shares of the company's stock after purchasing an additional 77,364 shares during the period. California
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Alumis Inc. (NASDAQ:ALMS) on Monday shared topline data from its ongoing ONWARD3 long-term extension study, demonstrating that its investigational oral therapy, envudeucitinib, achieved leading skin clearance rates for patients with immune-mediated diseases.
Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded as high as $28.64 and last traded at $28.78. 295,097 shares traded hands during trading, a decline of 86% from the average daily volume of 2,138,687 shares. The stock had previously closed at $27.23. Wall Street Analysts
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
California State Teachers Retirement System boosted its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 2,222.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 80,845 shares of the company's stock after purchasing an additional 77,364 shares during the period. California
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Alumis Inc. (NASDAQ:ALMS) on Monday shared topline data from its ongoing ONWARD3 long-term extension study, demonstrating that its investigational oral therapy, envudeucitinib, achieved leading skin clearance rates for patients with immune-mediated diseases.
Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded as high as $28.64 and last traded at $28.78. 295,097 shares traded hands during trading, a decline of 86% from the average daily volume of 2,138,687 shares. The stock had previously closed at $27.23. Wall Street Analysts
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety, though not outright superiority versus competitors, and twice-daily dosing is a minor drawback. Upcoming 2026 catalysts include long-term psoriasis data, NDA submission, and pivotal SLE data, all critical for valuation and acquisition potential.
